Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE intensive lipid management in acute coronary syndrome
jRCT1020240029Completed
- Sponsor
- Novartis
- Start
- Oct 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rosuvastatin, atorvastatin, pitavastatin, ezetimibe, evolocumab and 1 more in acute coronary syndrome (ACS), myocardial infarction (MI), Myocardial Infarction (MI) and 3 more, sponsored by Novartis. Primary endpoint: LDL-C < 70 mg/dL at 6 months. Started Oct 2024; status: completed.
02
Drugs
rosuvastatinatorvastatinpitavastatinezetimibeevolocumab
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)Myocardial Infarction (MI)unstable anginahypercholesterolemia
Beyond the preview
Go deeper on jRCT1020240029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1020240029.